A Study Evaluating the Relation between the Clinical Benefit and Immune-Related Adverse Events (Iraes) of Nivolumab in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients
Latest Information Update: 28 Nov 2019
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 12 Nov 2017 New trial record
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer.